James Rosebrugh Leaming
James Rosebrugh Leaming | |
---|---|
Born | 1820 |
Died | 1892 |
Nationality | Canadian |
Occupation | Physician, Educator |
Known for | Contributions to medical education and pulmonary medicine |
James Rosebrugh Leaming (1820–1892) was a prominent Canadian-born physician and educator known for his significant contributions to medical education and the field of pulmonary medicine.
Early Life and Education[edit | edit source]
Leaming was born in 1820 in Ontario, Canada. He pursued his early education in Canada before moving to the United States to further his studies in medicine. He graduated from the College of Physicians and Surgeons in New York City.
Medical Career[edit | edit source]
After completing his education, Leaming began his medical practice in New York City. He quickly gained recognition for his expertise in pulmonary diseases, particularly tuberculosis. Leaming's work in this area was highly influential, and he became a leading figure in the study and treatment of respiratory illnesses.
Contributions to Medical Education[edit | edit source]
Leaming was also a dedicated educator. He served as a professor at several medical institutions, including the New York Medical College and the University of Illinois College of Medicine. His teaching methods and dedication to his students left a lasting impact on the field of medical education.
Later Life and Legacy[edit | edit source]
In his later years, Leaming moved to Chicago, Illinois, where he continued his medical practice and teaching. He passed away in 1892, leaving behind a legacy of significant contributions to both medicine and medical education.
See Also[edit | edit source]
- Pulmonary medicine
- Medical education
- Tuberculosis
- New York Medical College
- University of Illinois College of Medicine
References[edit | edit source]
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Prab R. Tumpati, MD